Arcturus Therapeutics Ltd (ARCT):製薬・医療:M&Aディール及び事業提携情報

GlobalDataが発行した調査報告書(DATA904C8190)
◆英語タイトル:Arcturus Therapeutics Ltd (ARCT) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA904C8190
◆発行会社(リサーチ会社):GlobalData
◆発行日:2018年10月
◆ページ数:43
◆レポート形式:英語 / PDF
◆納品方法:Eメール
◆調査対象地域:アメリカ
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD250 ⇒換算¥36,500見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥73,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥109,500見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送いたしますので、請求書発行日より2ヶ月以内に銀行振込にて支払をお願いします。
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規代理店です。同社発行の市場リサーチレポート及びリサーチサービスに関するお問い合わせは弊社までお願い致します。GlobalData社の概要及び新刊レポートはこちらでご確認いただけます。

【レポートの概要】

Summary
Arcturus Therapeutics Ltd (Arcturus), formerly Alcobra Ltd is a pharmaceutical company that develops a portfolio of nucleic acid therapeutics for treatment of diseases with unmet medical needs. It discovers and develops RNA medicines and design and utilize lipid-mediated drug delivery systems. Arcturus offers messenger RNA (mRNA), which can be used as protein replacement therapy to treat diseases caused by a lack of protein and by defective proteins such as cystic fibrosis. The company’s pipeline products include Lunar-OTC, Lunar-CF, Lunar-Rare1, Lunar-Rare2, Lunar-HBV, Lunar-NASH, ARB-1467, among others. Its RNA therapeutics includes programs pursuing rare diseases, Hepatitis B, non-alcoholic steatohepatitis (NASH), cystic fibrosis, and vaccines. Arcturus is headquartered in San Diego, California, the US.

Arcturus Therapeutics Ltd (ARCT) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
Arcturus Therapeutics Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Arcturus Therapeutics Ltd, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Arcturus Therapeutics Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Arcturus Therapeutics Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
Arcturus Therapeutics Ltd, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
Arcturus Therapeutics Ltd, Pharmaceuticals & Healthcare, Deal Details 11
Venture Financing 11
Arcturus Therapeutics Raises USD67.7 Million in Venture Financing 11
Arcturus Therapeutics Raises USD5.9 Million in Venture Financing 12
Arcturus Therapeutics Raises USD2.1 Million in Venture Financing 13
Arcturus Therapeutics Raises USD4.6 Million in Venture Financing 14
Partnerships 15
Curevac and Arcturus Therapeutics Enter into Co-Development Agreement 15
Merger 16
Alcobra Merges with Arcturus Therapeutics 16
Equity Offering 18
Arcturus Therapeutics to Raise USD30 million in Public Offering of Shares 18
Alcobra Raises USD41.5 Million in Public Offering of Shares 19
Alcobra Raises USD29.9 Million in Public Offering of Shares 21
Alcobra Completes Public Offering Of Shares For US$38 Million 23
Alcobra Completes IPO For US$25 Million 25
Acquisition 27
Regenera Pharma May Acquire 66.6% Stake in Alcobra Pharma 27
Arcturus Therapeutics Ltd – Key Competitors 28
Arcturus Therapeutics Ltd – Key Employees 29
Arcturus Therapeutics Ltd – Locations And Subsidiaries 30
Head Office 30
Other Locations & Subsidiaries 30
Recent Developments 31
Strategy And Business Planning 31
Jun 23, 2017: Alcobra Updates On Its Review Of Strategic Alternatives 31
Financial Announcements 32
Nov 09, 2017: Alcobra Announces Third Quarter 2017 Financial Results and Provides Corporate Update 32
Aug 11, 2017: Alcobra Announces Second Quarter 2017 Financial Results and Provides Corporate Update 33
May 30, 2017: Alcobra Announces First Quarter 2017 Financial Results and Provides Corporate Update 34
Feb 15, 2017: Alcobra Announces Fourth-Quarter and Full-Year 2016 Financial Results and Provides Corporate Update 35
Corporate Communications 36
Aug 28, 2018: Arcturus Therapeutics names Andrew Sassine as interim Chief Financial Officer 36
May 31, 2018: Arcturus Announces Management Appointments; Company Founder Joseph E. Payne Reinstated as President and CEO 37
May 29, 2018: Arcturus Therapeutics Appoints Four New Directors and Reaches Settlement Agreement with Founder Joseph E. Payne 38
May 15, 2017: Alcobra Announces Leadership Update 40
Legal and Regulatory 41
May 23, 2018: Arcturus Therapeutics Comments on Court Ruling on Undisclosed Group Organized by Joseph E. Payne and his Associates in Violation of Regulation 13D 41
Product Approvals 42
Feb 06, 2017: Alcobra Reports on Productive FDA Meeting for New Lead Product Candidate for ADHD 42
Appendix 43
Methodology 43
About GlobalData 43
Contact Us 43
Disclaimer 43

List of Tables
Arcturus Therapeutics Ltd, Pharmaceuticals & Healthcare, Key Facts, 2017 2
Arcturus Therapeutics Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Arcturus Therapeutics Ltd, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Arcturus Therapeutics Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Arcturus Therapeutics Ltd, Deals By Therapy Area, 2012 to YTD 2018 9
Arcturus Therapeutics Ltd, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
Arcturus Therapeutics Raises USD67.7 Million in Venture Financing 11
Arcturus Therapeutics Raises USD5.9 Million in Venture Financing 12
Arcturus Therapeutics Raises USD2.1 Million in Venture Financing 13
Arcturus Therapeutics Raises USD4.6 Million in Venture Financing 14
Curevac and Arcturus Therapeutics Enter into Co-Development Agreement 15
Alcobra Merges with Arcturus Therapeutics 16
Arcturus Therapeutics to Raise USD30 million in Public Offering of Shares 18
Alcobra Raises USD41.5 Million in Public Offering of Shares 19
Alcobra Raises USD29.9 Million in Public Offering of Shares 21
Alcobra Completes Public Offering Of Shares For US$38 Million 23
Alcobra Completes IPO For US$25 Million 25
Regenera Pharma May Acquire 66.6% Stake in Alcobra Pharma 27
Arcturus Therapeutics Ltd, Key Competitors 28
Arcturus Therapeutics Ltd, Key Employees 29
Arcturus Therapeutics Ltd, Subsidiaries 30

List of Figures
Arcturus Therapeutics Ltd, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Arcturus Therapeutics Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Arcturus Therapeutics Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Arcturus Therapeutics Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Arcturus Therapeutics Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Arcturus Therapeutics Ltd, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7
Arcturus Therapeutics Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Arcturus Therapeutics Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9

【免責事項】
http://www.globalresearch.jp/disclaimer

★リサーチレポート[ Arcturus Therapeutics Ltd (ARCT):製薬・医療:M&Aディール及び事業提携情報(Arcturus Therapeutics Ltd (ARCT) - Pharmaceuticals & Healthcare - Deals and Alliances Profile)]についてメールでお問い合わせはこちらでお願いします。

◆H&Iグローバルリサーチのお客様(例)◆